FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207020992> ?p ?o ?g. }

• W4207020992 endingPage "602" @default.
• W4207020992 startingPage "587" @default.
• W4207020992 abstract "The risk of thromboembolic events or death in patients treated with intravitreal anti-vascular endothelial growth factor (IVT anti-VEGF) is poorly described on a large scale and by molecule. This study aimed to assess the risk of myocardial infarction (MI), stroke, or death in new users of IVT aflibercept versus ranibizumab in real-world practice.A nationwide cohort study using the French National Health Insurance databases covering 99% of the French population was conducted in patients aged 18 years or older who initiated IVT therapy with ranibizumab or aflibercept between 2014 and 2018. Patients were followed for up to 6 years until December 31, 2019. The risks of MI, stroke, and death were compared in new aflibercept versus ranibizumab users using Kaplan-Meier and multivariate Cox proportional hazards models adjusted on sociodemographic characteristics and cardiovascular disease or risk factors. Subgroup analyses were performed according to history of ischemic heart disease or stroke, diabetes, indication for treatment, sex, age, and number of IVT anti-VEGF injections.When compared to new users of ranibizumab (n = 174,794, mean age 76.0 ± 11.9 years, 59.2% female), new users of aflibercept (n = 76,242, mean age 76.6 ± 11.2 years, 59.2% female) did not have an increased risk of MI (n = 1523 incident MI, adjusted hazard ratio [aHR] 1.00; 95% CI 0.89-1.11), stroke (n = 2306 incident strokes, aHR 1.03; 95% CI 0.95-1.13), or death (n = 4135 deaths, aHR 0.98; 95% CI 0.92-1.05). However, a small but non-statistically significant increase in the risk of stroke was observed in new users of aflibercept versus ranibizumab among patients with diabetes (aHR 1.15; 95% CI 0.98-1.35), particularly those with diabetic macular edema (aHR 1.20; 95% CI 1.00-1.44). The remaining subgroup analyses did not change the results.Aflibercept and ranibizumab appear to have similar safety profiles with respect to the risk of MI, stroke, or death under real-world conditions of use." @default.
• W4207020992 created "2022-01-26" @default.
• W4207020992 creator A5028195839 @default.
• W4207020992 creator A5039305826 @default.
• W4207020992 creator A5059005646 @default.
• W4207020992 creator A5060852348 @default.
• W4207020992 date "2022-01-22" @default.
• W4207020992 modified "2023-09-25" @default.
• W4207020992 title "Risk of Myocardial Infarction, Stroke, or Death in New Users of Intravitreal Aflibercept Versus Ranibizumab: A Nationwide Cohort Study" @default.
• W4207020992 cites W1481978003 @default.
• W4207020992 cites W1612683729 @default.
• W4207020992 cites W1849521086 @default.
• W4207020992 cites W1968189763 @default.
• W4207020992 cites W2001555880 @default.
• W4207020992 cites W2004117352 @default.
• W4207020992 cites W2016722530 @default.
• W4207020992 cites W2017314392 @default.
• W4207020992 cites W2037978728 @default.
• W4207020992 cites W2061862339 @default.
• W4207020992 cites W2068230682 @default.
• W4207020992 cites W2101874912 @default.
• W4207020992 cites W2105202086 @default.
• W4207020992 cites W2123251249 @default.
• W4207020992 cites W2124415048 @default.
• W4207020992 cites W2201646748 @default.
• W4207020992 cites W2378098209 @default.
• W4207020992 cites W2461692414 @default.
• W4207020992 cites W2509759140 @default.
• W4207020992 cites W2578733585 @default.
• W4207020992 cites W2617556060 @default.
• W4207020992 cites W2669540614 @default.
• W4207020992 cites W2763745409 @default.
• W4207020992 cites W2786599866 @default.
• W4207020992 cites W2895211690 @default.
• W4207020992 cites W2913437590 @default.
• W4207020992 cites W2995833605 @default.
• W4207020992 cites W3023534265 @default.
• W4207020992 cites W3033186605 @default.
• W4207020992 cites W3048155870 @default.
• W4207020992 cites W3093187878 @default.
• W4207020992 cites W3170700786 @default.
• W4207020992 doi "https://doi.org/10.1007/s40123-021-00451-1" @default.
• W4207020992 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35072917" @default.
• W4207020992 hasPublicationYear "2022" @default.
• W4207020992 type Work @default.
• W4207020992 citedByCount "1" @default.
• W4207020992 countsByYear W42070209922022 @default.
• W4207020992 crossrefType "journal-article" @default.
• W4207020992 hasAuthorship W4207020992A5028195839 @default.
• W4207020992 hasAuthorship W4207020992A5039305826 @default.
• W4207020992 hasAuthorship W4207020992A5059005646 @default.
• W4207020992 hasAuthorship W4207020992A5060852348 @default.
• W4207020992 hasBestOaLocation W42070209921 @default.
• W4207020992 hasConcept C126322002 @default.
• W4207020992 hasConcept C127413603 @default.
• W4207020992 hasConcept C207103383 @default.
• W4207020992 hasConcept C2776694085 @default.
• W4207020992 hasConcept C2777802072 @default.
• W4207020992 hasConcept C2778749236 @default.
• W4207020992 hasConcept C2780645631 @default.
• W4207020992 hasConcept C2781100027 @default.
• W4207020992 hasConcept C2908647359 @default.
• W4207020992 hasConcept C44249647 @default.
• W4207020992 hasConcept C500558357 @default.
• W4207020992 hasConcept C50382708 @default.
• W4207020992 hasConcept C71924100 @default.
• W4207020992 hasConcept C72563966 @default.
• W4207020992 hasConcept C78519656 @default.
• W4207020992 hasConcept C99454951 @default.
• W4207020992 hasConceptScore W4207020992C126322002 @default.
• W4207020992 hasConceptScore W4207020992C127413603 @default.
• W4207020992 hasConceptScore W4207020992C207103383 @default.
• W4207020992 hasConceptScore W4207020992C2776694085 @default.
• W4207020992 hasConceptScore W4207020992C2777802072 @default.
• W4207020992 hasConceptScore W4207020992C2778749236 @default.
• W4207020992 hasConceptScore W4207020992C2780645631 @default.
• W4207020992 hasConceptScore W4207020992C2781100027 @default.
• W4207020992 hasConceptScore W4207020992C2908647359 @default.
• W4207020992 hasConceptScore W4207020992C44249647 @default.
• W4207020992 hasConceptScore W4207020992C500558357 @default.
• W4207020992 hasConceptScore W4207020992C50382708 @default.
• W4207020992 hasConceptScore W4207020992C71924100 @default.
• W4207020992 hasConceptScore W4207020992C72563966 @default.
• W4207020992 hasConceptScore W4207020992C78519656 @default.
• W4207020992 hasConceptScore W4207020992C99454951 @default.
• W4207020992 hasIssue "2" @default.
• W4207020992 hasLocation W42070209921 @default.
• W4207020992 hasLocation W42070209922 @default.
• W4207020992 hasLocation W42070209923 @default.
• W4207020992 hasLocation W42070209924 @default.
• W4207020992 hasLocation W42070209925 @default.
• W4207020992 hasLocation W42070209926 @default.
• W4207020992 hasLocation W42070209927 @default.
• W4207020992 hasOpenAccess W4207020992 @default.
• W4207020992 hasPrimaryLocation W42070209921 @default.
• W4207020992 hasRelatedWork W2258895757 @default.
• W4207020992 hasRelatedWork W2411983015 @default.
• W4207020992 hasRelatedWork W2413342745 @default.

• next